GlassScriptPhysician profile
Robert Edward Leblond
NPI 1699727008
$3,470.91
in general payments reported to CMS, 2019-2025
25 companies · $978 in 2025
The $978 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $132 · 2021: $459 · 2022: $340 · 2023: $240 · 2024: $914 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,131.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $779.59 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Spr Therapeutics, INC | $426.57 | 2020-2024 | Sprint Pns System |
| Medtronic, INC. | $339.09 | 2021-2025 | Inceptiv |
| Nevro Corp. | $243.60 | 2019-2024 | Senza |
| Amgen INC. | $211.54 | 2019 | |
| Averitas Pharma INC. | $197.52 | 2023-2025 | Qutenza |
| Globus Medical, INC. | $171.30 | 2025 | Senza |
| Abbvie INC. | $171.05 | 2024-2025 | |
| Spinal Simplicity, LLC | $151.72 | 2023 | Ha Minuteman G3-R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.19 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $134.88 | 2024-2025 | Belbuca |
| Grt US Holding, INC. | $120.19 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $58.32 | 2024-2025 | |
| Medtronic USA, INC. | $56.01 | 2019 | |
| Scilex Pharmaceuticals INC. | $42.65 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $35.95 | 2025 | Movantik |
| Hikma Pharmaceuticals USA | $34.95 | 2022 | |
| Daiichi Sankyo INC. | $30.49 | 2019 | |
| Assertio Therapeutics, INC. | $28.54 | 2019 | |
| Boston Scientific Corporation | $23.13 | 2024 | |
| Tonix Medicines, INC. | $18.89 | 2025 | Tonmya |
| Depuy Synthes Sales INC. | $16.15 | 2019 | |
| Abbott Laboratories | $14.29 | 2025 | Octrode |
| Allergan, INC. | $13.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Leblond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.